Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- BLIN +17.5%, BB +7.3%, MU +7.1%, FDX +2%, GIS +0.2%.
In Reaction to Strong MU earnings report:
- AMAT +2.2%, LRCX +2%, INTC +1%, NVDA +1%, WDC +0.9%,AMD +0.9%, STX +0.8%.
Notable Crypto Plays:
- SSC +55.8%, LFIN +18.7%, FTFT +13.6%, XNET +8.0%, OTIV+7.5%, DPW +6.1%, GROW +4.3%, SRAX +3.8%, MARA +2.9%, RIOT +2.3%.
Other news:
- SKLN +21.1% (to purchase an equity stake in Helomics Corporation),
- GSUM +13.9% (Launches AI-driven, Software as a Service, Intelligent CRM Solution for the China market),
- EXEL +5.3% (continued strength after FDA approval of CABOMETYX tablets for previously untreated advanced renal cell carcinoma),
- TIG +1.9% (Announces plans to focus its resources and capabilities on its eASC platform technology and its product candidates Cx601 and Cx611),
- BIIB +1.6% (Ionis Pharma and Biogen enter collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy),
- AL +1.4% (slightly higher in after hours following upgrade to Buy at Buckingham ),
- UPS +0.8% (following FDX results).
Analyst comments:
- QHC +5.4% (Upgraded to Equal-Weight from Underweight at Morgan Stanley),
- AKS +2.5% (Upgraded to Buy from Neutral at Longbow),
- X +2.1% (Upgraded to Buy from Neutral at Longbow),
- WEN +1.8% (Upgraded to Outperform from Neutral at Wedbush),
- WTW +1.6% (Initiated with a Buy at B. Riley FBR, Inc.; tgt $65),
- BIIB +1.6% (Upgraded to Outperform from Neutral at Credit Suisse),
- UAL +1.3% (Upgraded to Buy from Neutral at Buckingham Research),
- AA +1.1% (Upgraded to Outperform from Neutral at Credit Suisse),
- TS +1.1% (Initiated with a Overweight at Barclays; tgt $39),
- NUE +0.9% (Upgraded to Buy from Neutral at Longbow).